The valuation of CAVH depends on its ability to maintain concentrations
of uraemic toxins in the blood at acceptable low
levels and simultaneously achieve a normal balance between
fluids and electrolytes. It rapidly corrects metabolic acidosis
without the need to remove large volumes of plasma and provides cardiovascular stability by increasing the cardiac output and by minimising peripheral resistance.